In our study, we report that while ANGPTL4 is highly upregulated in ccRCC compared to other types of cancers and normal kidney tissues, there is a cohort of 15% of patients in whom ANGPTL4 is not elevated, and these patients without elevated ANGPTL4 had a worse prognosis than those with high ANGPTL4. This evidence concerns the gene ANGPTL4 and cancer.